Your browser is no longer supported. Please, upgrade your browser.
Settings
ACOR Acorda Therapeutics, Inc. daily Stock Chart
ACOR [NASD]
Acorda Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.98 Insider Own1.50% Shs Outstand47.47M Perf Week15.56%
Market Cap148.11M Forward P/E- EPS next Y-2.94 Insider Trans-0.21% Shs Float47.38M Perf Month-54.05%
Income-94.20M PEG- EPS next Q-0.77 Inst Own- Short Float29.88% Perf Quarter-69.29%
Sales306.20M P/S0.48 EPS this Y108.70% Inst Trans3.17% Short Ratio10.73 Perf Half Y-76.75%
Book/sh11.94 P/B0.26 EPS next Y-7.30% ROA2.60% Target Price10.33 Perf Year-89.30%
Cash/sh7.23 P/C0.43 EPS next 5Y29.00% ROE5.70% 52W Range2.27 - 29.75 Perf YTD-79.97%
Dividend- P/FCF1.26 EPS past 5Y0.20% ROI3.90% 52W High-89.51% Beta1.46
Dividend %- Quick Ratio4.00 Sales past 5Y7.00% Gross Margin78.70% 52W Low37.44% ATR0.38
Employees474 Current Ratio4.30 Sales Q/Q-58.50% Oper. Margin12.60% RSI (14)32.13 Volatility10.22% 13.74%
OptionableYes Debt/Eq0.61 EPS Q/Q-469.10% Profit Margin11.00% Rel Volume0.93 Prev Close3.18
ShortableYes LT Debt/Eq0.61 EarningsAug 01 AMC Payout0.00% Avg Volume1.32M Price3.12
Recom3.00 SMA20-19.31% SMA50-46.67% SMA200-74.51% Volume1,225,586 Change-1.89%
Aug-14-19Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19Initiated Wedbush Neutral
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Nov-09-17Initiated Oppenheimer Perform
Nov-08-17Initiated H.C. Wainwright Buy $35
Oct-06-17Resumed Goldman Sell $20
Jul-11-17Initiated Jefferies Hold
Apr-03-17Downgrade JP Morgan Overweight → Neutral
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jun-09-15Initiated Guggenheim Neutral
Aug-23-19 09:15AM  Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 7.5% Zacks
07:38AM  Retrophin Down on Neurological Disorder Drug Study Failure Zacks
Aug-21-19 06:03PM  Synlogic Discontinues Development of SYNB1020, Stock Down Zacks
08:42AM  Moderna (MRNA) Jumps: Stock Rises 5.6% Zacks
Aug-20-19 08:34AM  Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment Zacks +9.90%
07:44AM  Acorda Therapeutics Enters Oversold Territory Zacks
Aug-14-19 09:10AM  Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD Zacks -12.45%
Aug-13-19 09:50AM  Regeneron Ebola Treatment Shows Promise, Study Stopped Early Zacks
Aug-12-19 08:37AM  Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates Zacks
Aug-09-19 11:09AM  Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat Zacks
Aug-08-19 10:45AM  Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2 Zacks
10:15AM  Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates Zacks
09:26AM  Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates Zacks
Aug-07-19 05:40PM  Edited Transcript of ACOR earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-02-19 11:54AM  Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark Zacks -48.93%
10:53AM  Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates Zacks
10:52AM  Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates Zacks
10:48AM  Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss Zacks
10:43AM  IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus Zacks
08:24AM  Acorda Therapeutics (ACOR) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 06:45PM  Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates Zacks -12.41%
04:00PM  Acorda Provides Update for Second Quarter Ended June 30, 2019 Business Wire
12:02PM  Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales Zacks
12:00PM  Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View Zacks
09:54AM  Amgen (AMGN) Catches Eye: Stock Jumps 5.7% Zacks
Jul-31-19 11:32AM  Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance Zacks
Jul-26-19 10:38AM  Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2 Zacks
08:30AM  Acorda Receives Positive CHMP Opinion for INBRIJA (levodopa inhalation powder) Business Wire
Jul-25-19 11:25AM  Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View Zacks
11:10AM  Acorda (ACOR) to Post Q2 Earnings: What's in the Cards? Zacks
10:33AM  Analysts Estimate Acorda Therapeutics (ACOR) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-24-19 05:50PM  Acorda Therapeutics (ACOR) Outpaces Stock Market Gains: What You Should Know Zacks
01:54PM  Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised Zacks
Jul-19-19 09:41AM  Horizon's NDA for Procysbi New Dosage Form Accepted by FDA Zacks
Jul-18-19 07:00AM  Acorda Second Quarter 2019 Update:  Webcast/Conference Call Scheduled for August 1, 2019 Business Wire
Jul-16-19 01:15PM  Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study Zacks
Jul-11-19 11:14AM  FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
09:05AM  Horizon Therapeutics Files BLA to FDA for Eye Disease Drug Zacks
Jul-10-19 09:20AM  Is Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Balance Sheet A Threat To Its Future? Simply Wall St.
Jul-08-19 06:02PM  ObsEva Ends Recruitment in Second Uterine Fibroids Study Zacks
Jul-05-19 12:04PM  Catalyst Pharma Focuses on Firdapse Launch & Label Expansion Zacks
Jul-03-19 09:00AM  All You Need to Know About Acorda (ACOR) Rating Upgrade to Buy Zacks
Jun-28-19 09:56AM  Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View Zacks
Jun-27-19 10:18AM  Inovio Up on Enrollment Closure in Cervical Dysplasia Study Zacks +6.78%
Jun-26-19 06:17PM  Pacira Gets EMA Acceptance for Pain Management Drug Exparel Zacks
08:42AM  Revance Therapeutics (RVNC) Jumps: Stock Rises 5.2% Zacks
06:11AM  Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin Zacks
06:07AM  Conatus' Emricasan Lags Primary Goal in Liver Function Study Zacks
Jun-25-19 08:00AM  Alnylam Presents New Data for RNAi Therapeutic Onpattro Zacks
Jun-24-19 05:53PM  Epizyme Announces Positive Interim Data on Lead Candidate Zacks
05:45PM  AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire Zacks
11:04AM  BioMarin Gets $15M From Pfizer on Talzenna's European Nod Zacks
10:05AM  Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children Zacks
Jun-21-19 11:05AM  Alexion's sBLA for Ultomiris Gets Priority Review From FDA Zacks
Jun-20-19 03:31PM  Heres What Hedge Funds Think About Acorda Therapeutics Inc (ACOR) Insider Monkey
09:35AM  Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study Zacks
Jun-19-19 04:07PM  Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH Zacks
09:40AM  Intrexon Up on Striking 100M Cannabinoid Deal With Surterra Zacks
08:40AM  Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher Zacks
Jun-18-19 10:38AM  Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod Zacks
10:27AM  Protalix (PLX) Completes Enrollment in Fabry Disease Study Zacks
08:50AM  Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session Zacks
Jun-17-19 06:17PM  Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy Zacks
Jun-14-19 05:25PM  Dr. Reddy's Inks Deal to Sell Neurology Branded Products Zacks
Jun-13-19 05:46PM  Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi Zacks +6.89%
10:26AM  NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag Zacks
10:15AM  Acorda Therapeutics Enters Oversold Territory Zacks
Jun-12-19 10:30AM  Denali's Hunter Syndrome Candidate Gets Orphan Drug Status Zacks -6.82%
Jun-10-19 06:06PM  Athenex Rallies on Positive Early Data on Psoriasis Candidate Zacks
Jun-06-19 10:33AM  BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady Zacks -7.28%
10:29AM  Reata's (RETA) Kidney Candidate Gets Orphan Drug Status Zacks
Jun-05-19 09:02AM  Myriad Genetics Announces Study Results Of myRisk Cancer Test Zacks -6.49%
Jun-04-19 05:30PM  Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR Zacks
11:52AM  Emergent (EBS) Wins HHS Contract to Supply VIGIV Product Zacks
10:26AM  Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down Zacks
Jun-03-19 07:00AM  Acorda Therapeutics Debuts Art Exhibition Inspired by People with Parkinsons at the 5th World Parkinson Congress Business Wire
Jun-01-19 09:31AM  Acorda (ACOR) Down 11.3% Since Last Earnings Report: Can It Rebound? Zacks
May-31-19 10:46AM  Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure Zacks
May-30-19 04:51PM  Mesoblast Starts Rolling BLA Submission for Remestemcel-L Zacks
08:50AM  Chiasma (CHMA) Catches Eye: Stock Jumps 9.7% Zacks
May-29-19 08:40AM  Fate Therapeutics (FATE) Surges: Stock Moves 6.8% Higher Zacks
May-28-19 11:25AM  REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4% Zacks
May-23-19 09:06AM  Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE PR Newswire -6.29%
07:00AM  Acorda Therapeutics to Present at Jefferies 2019 Healthcare Conference Business Wire
May-09-19 11:23AM  Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy? Insider Monkey
May-06-19 09:16AM  Edited Transcript of ACOR earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-04-19 04:23PM  Acorda Therapeutics (ACOR) Q1 2019 Earnings Call Transcript Motley Fool
May-02-19 11:44AM  Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1 Zacks +5.27%
08:16AM  The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data Benzinga
07:30AM  Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:12AM  Acorda: 1Q Earnings Snapshot Associated Press
06:00AM  Acorda Provides Update for First Quarter Ended March 31, 2019 Business Wire
Apr-25-19 10:33AM  Earnings Preview: Acorda Therapeutics (ACOR) Q1 Earnings Expected to Decline Zacks
Apr-22-19 02:13PM  Should You Be Concerned About Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Historical Volatility? Simply Wall St.
Apr-18-19 07:00AM  Acorda First Quarter 2019 Update: Webcast/Conference Call Scheduled for May 2, 2019 Business Wire
Apr-11-19 10:04AM  Acorda to Gain From Inbrija Sales and Neurological Pipeline Zacks
Mar-19-19 07:00AM  Acorda to Present New Long-Term Data for INBRIJA (levodopa inhalation powder) at Academy of Managed Care Pharmacy Annual Meeting Business Wire
Mar-16-19 09:30AM  Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound? Zacks
Mar-15-19 05:45PM  Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know Zacks
03:28PM  Should You Be Concerned About Acorda Therapeutics, Inc.s (NASDAQ:ACOR) ROE? Simply Wall St.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sabella Lauren MChief Commercial OfficerFeb 22Sale13.1876110,0285,092Feb 25 04:19 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOFeb 22Sale13.1876110,0285,092Feb 25 04:17 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 30Sale16.017,000112,0394,750,219Feb 01 04:28 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 25Sale16.002,40138,4164,757,219Jan 28 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 24Sale16.038,600137,8514,759,620Jan 28 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 23Sale16.0145,898734,9424,768,220Jan 24 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 22Sale16.0251,945831,9724,814,118Jan 24 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 18Sale16.2439,358639,3274,866,063Jan 22 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 17Sale16.86100,0001,685,5504,905,421Jan 22 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 16Sale16.9491,6501,552,4145,005,421Jan 17 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 15Sale16.601,70028,2235,097,071Jan 17 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 11Sale17.4040,392702,7885,098,771Jan 15 04:32 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 10Sale17.2987,4911,512,7285,139,163Jan 11 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 09Sale17.0575,0001,278,7055,226,654Jan 11 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 08Sale16.2459,174960,9275,301,654Jan 09 04:22 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 07Sale16.5675,0001,241,7385,360,828Jan 09 04:22 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 04Sale16.6131,591524,7145,435,828Jan 07 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 03Sale15.7423,616371,6455,467,419Jan 07 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 28Sale14.9952,891792,7515,491,035Jan 02 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 27Sale14.6650,000732,7605,543,926Dec 28 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 26Sale14.6650,000732,8205,593,926Dec 28 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 21Sale13.2440,506536,0975,643,926Dec 26 04:14 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 20Sale14.0340,000561,3685,684,432Dec 21 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 19Sale15.935,00079,6645,724,432Dec 21 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 18Sale16.9480,0001,354,9415,729,432Dec 19 04:10 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 17Sale16.4941,853690,1025,809,432Dec 19 04:10 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 14Sale16.1528,796464,9785,851,285Dec 17 05:48 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 13Sale16.2733,061537,7605,880,081Dec 17 05:48 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 12Sale16.30100,0001,629,7905,913,142Dec 13 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 11Sale16.30200,0003,259,5006,013,142Dec 13 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 10Sale19.0735,000667,5316,213,142Dec 11 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 07Sale18.7725,210473,0716,248,142Dec 11 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 06Sale18.4340,711750,3406,273,352Dec 07 04:45 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 04Sale20.603,09063,6596,314,063Dec 07 04:45 PM
Wasman JanePresident, Intl and GCDec 03Sale20.523,06762,947105,287Dec 06 08:42 AM
Sabella Lauren MChief Commercial OfficerDec 03Sale20.565,191106,7371,568Dec 06 08:31 AM
LAWRENCE DAVIDChief, Bus. Ops & PAODec 03Sale20.552,49351,2323,653Dec 06 08:22 AM
Hindman Andrew A.Chief Business OfficerDec 03Sale20.5675315,4785,171Dec 06 08:05 AM
COHEN RONPresident and CEODec 03Sale20.603,62074,554487,554Dec 06 08:00 AM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 03Sale20.70100,0002,069,5006,317,153Dec 03 05:03 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerNov 30Sale20.4875,0001,536,0156,417,153Dec 03 05:03 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerNov 29Sale20.2050,0001,009,8606,492,153Dec 03 05:03 PM
Randall LorinDirectorNov 26Sale19.981,90438,0340Nov 28 08:02 AM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 11Sale17.0949,760850,5486,542,153Oct 12 04:16 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 10Sale16.9193,8161,586,7576,591,913Oct 12 04:16 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 09Sale16.4956,290928,0766,685,729Oct 09 05:56 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 08Sale17.8760,0421,073,1976,742,019Oct 09 05:56 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 05Sale17.5137,526657,0546,802,061Oct 09 05:56 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 04Sale18.8937,526708,7506,839,587Oct 04 06:59 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 03Sale19.4856,2891,096,2796,877,113Oct 04 06:59 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerOct 02Sale18.8932,649616,7046,933,402Oct 04 06:59 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerSep 06Sale27.8213,829384,6837,106,955Sep 06 04:14 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerSep 04Sale29.002005,8007,120,784Sep 06 04:14 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerAug 28Sale29.4120,256595,6587,120,984Sep 06 04:14 PM